of noninvasive and clinically useful methods to detect mitochondrial dysfunction.
Mitochondrial DNA (mtDNA) is a circular doublestranded DNA inherited maternally that contains only 37 genes, which encode for proteins involved in oxidative phosphorylation, transfer-RNA, and ribosomal-RNA. 10 mtDNA is housed in the mitochondrial matrix, encased within a double-membrane system composed of the outer and inner mitochondrial membranes. However, as a consequence of mitochondrial injury, fragments of mtDNA, known as mitochondrial damage-associated molecular patterns, may escape from the matrix to the cytosol and then to the systemic circulation. 11 In the kidney, disruption of mitochondrial integrity (eg, because of hyperfiltration or renal hypoxia) may result in release of mtDAMPs into the urine, where they serve as surrogate markers of renal mitochondrial injury. Indeed, a recent study showed that urinary mtDNA is associated with progression of renal dysfunction in patients with acute kidney injury after cardiac surgery. 12 However, whether this sign of mitochondrial injury can be detected in the urine of patients with hypertension has not been determined.
Thus, this study was designed to test the hypothesis that hypertension would be associated with increasing urinary mtDNA copy numbers that parallel decrements in renal function. For this purpose, we measured urinary levels of mitochondriaencoded cytochrome-c oxidase-3 (COX3) and nicotinamide adenine dinucleotide (NADH) dehydrogenase subunit-1 (ND1) in healthy volunteers (HV) or patients with hypertension of 2 different causes: essential hypertension (EH) or RVH.
Methods
This study was performed at Mayo Clinic in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act guidelines and after approval of the institutional review board.
Study Population
Patients with EH (n=25) and RVH (n=34) participating in previously reported inpatient protocol studies 13 were prospectively enrolled after providing written informed consent. For controls, blood and urine samples were collected through the Mayo Clinic Biobank from 22 consenting healthy individuals. Furthermore, a validation cohort including additional RVH and HV subjects (n=10 each) was studied to further assess urinary mtDNA copy numbers.
Patients with EH were recruited if their blood pressure ≥140/90 mm Hg, they had a previous diagnosis of EH, or they have current use of antihypertensive medications. RVH patients (blood pressure ≥140/90 mm Hg and current use of antihypertensive medications) were included using entry criteria analogous to those required for enrollment in the Cardiovascular Outcomes for Renal Atherosclerotic Lesions (CORAL) trial.
14 RVH was defined as magnetic resonance or computed tomography angiography showing significant stenosis (>60%) or poststenotic dilation or renal artery Doppler ultrasound velocities across the stenosis >300 cm/s. Patients with uncontrolled hypertension (systolic blood pressure [SBP] >180 mm Hg, despite antihypertensive therapy), serum creatinine ≥2.5 mg/dL, diabetes mellitus requiring medications, recent cardiovascular events (myocardial infarction, stroke, and congestive heart failure within 6 months), pregnancy, and kidney transplant were excluded. EH and RVH patients were all maintained under controlled sodium intake (150 mEq/d) and antihypertensive therapy (diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers at usual recommended daily dose) for 3 days during collection of all samples. RVH patients were subsequently treated with medical therapy without (n=20) or with (n=14) renal stent revascularization and returned for repeat measurements 3 months after therapy. Patients were selected for renal revascularization on clinical grounds of (1) progressive, refractory hypertension or (2) recent progression of renal insufficiency or episodes of circulatory congestion. Technically successful revascularization was confirmed by a completion angiogram after the end of the procedure, indicating full restoration of renal artery patency.
HV were recruited if they had blood pressure ≤130/80 mm Hg, did not take any medications for hypertension, asthma, dementia, statins, or other lipid-lowering drugs (according to algorithms from electronic Medical Records and Genomics), 15 and had no history of hypertension, diabetes mellitus, congestive heart failure, coronary artery disease, stroke, or peripheral artery disease.
Clinical Data Collection and Laboratory Measurements
Demographics and laboratory data were obtained at study entry from our electronic database. Total cholesterol, low-density lipoprotein, and serum creatinine were measured by standard procedures. Estimated glomerular filtration rate (eGFR) was calculated using the chronic kidney disease epidemiology collaboration formula. 16 Urine samples were collected in all hypertensive patients (24-hour urine collections) and HV (spot urine sample), centrifuged, and the supernatant was stored. Urine protein levels and (only in EH and RVH) 24-hour total protein and albumin excretion were measured by standard procedures.
Plasma and Urine mtDNA
In all patients, plasma and urinary COX3 and ND1 levels were measured by quantitative real-time polymerase chain reaction. Furthermore, in RVH patients, urinary mtDNA copy numbers were measured again 3 months after treatment with medical therapy with or without renal revascularization.
DNA was isolated from plasma (200 µL) and urine (1.75 mL) samples using plasma and urine DNA isolation kits from Qiagen (Venlo, Netherlands; catalog number 51104) and Norgen Biotek (Ontario, Canada; catalog number 18100), respectively. Isolated DNAs were eluted in the total volume of 150 µL of elution buffer. DNA concentrations were measured by a NanoDrop Spectrophotometer. DNA (7.2 ng) from each sample was put into polymerase chain reaction reactions. Both COX3 (forward 5′-AGGCATCACCCCGCTAAATC-3′ and reverse 5′-GGTGAGCTCAGGTGATTGATACTC-3′) and ND1 (forward 5′-AGTCACCCTAGCCATCATTCTACT-3′ and reverse 5′-GGAGTAATCAGAGGTGTTCTTGTGT-3′) primers and TaqMan copy number assays were purchased from Life Technology (Carlsbad, CA). To calculate the absolute copy numbers of DNA in each sample, COX3 (Blue Heron BioTechnology, Bothell, WA; NC0129201) and ND1 (OriGene, Rockville, MD; SC101172) plasmid constructs (see the online-only Data Supplement) were diluted to generate serial dilutions and run together with the samples. Polymerase chain reaction was done on Applied Biosystems ViiA7 Real-Time PCR systems using the following conditions: 50 °C for 2 minutes, 95 °C for 10 minutes, and 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. COX3 and ND1 levels were corrected to the nuclear control gene RNAse-P (Invitrogen, catalog number 4403326) using a human genomic DNA for the standard curve (Invitrogen, catalog number 360486) and urinary creatinine (Arbor Assays, catalog number K002-H1) and expressed as copies per microliter, and their changes 3 months after medical therapy with or without renal revascularization as delta (3 months-baseline).
Renal Injury Markers
Urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule (KIM)-1 levels were measured by ELISA according to manufacturer's protocol (BioPorto Diagnostics, Hellerup, Denmark; catalog number KIT 036 and R&D Systems, Minneapolis, MN, catalog number DKM100, respectively), as previously described.
Renal Blood Flow and Oxygenation
Renal blood flow (RBF) was assessed by multidetector computed tomography using a dual-source 64-slice helical scanner (SOMATOM Definition; Siemens Medical Solutions), as previously described. 18 In brief, a 5F pigtail Cobra catheter (Cook, Inc, Bloomington, IN) was placed into the right atrium via the femoral or internal jugular vein (using a 6F sheath) for contrast media injections. Kidneys were scanned during respiratory suspension after a bolus injection of iopamidol-370 (0.5 mL/kg, ≤40 mL and 15 mL/s). Images were analyzed using the software package ANALYZE (Biomedical Imaging Resource Center, Mayo Clinic, Rochester, MN). Regions of interest were selected from cross-sectional images from the aorta, renal cortex, and medulla of both kidneys. Average tissue attenuation curves were fitted by curve-fitting algorithms to calculate hemodynamics in cortical and medullary regions of the kidney. Single-kidney RBF was calculated by multiplying kidney volume (ml of tissue) by renal perfusion (ml/min per ml of tissue), as previously described. 19 Renal oxygenation was detected by blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) on a GE Twin Speed Signa EXCITE 3.0T system (GE Medical Systems, Waukesha, WI), and intrarenal hypoxia expressed as R 2 *, an index of deoxyhemoglobin concentration in the kidney. Scans were performed under suspended respiration consisting of a 2D fast spoiled gradient echo sequence with multiple echo times, as previously described.
20 T2*-weighted images were analyzed and cortical and medullary regions of interest traced through the midpole hilar region of each kidney, which were subsequently transferred to the corresponding R 2 * parametric image, and processed using Matlab 7.10 (The MathWorks, Inc, Natick, MA). Fractional renal hypoxia, which mainly represents the medulla, was defined as the percentage of voxels from the whole 
Statistical Analysis
The analysis was performed with the statistical software JMP version 10.0 (SAS Institute, Inc, Cary, NC). The Shapiro-Wilk test was used to test for deviation from normality. Normally distributed data, expressed as mean±SD, were compared using ANOVA with Tukey post hoc test. Non-normally distributed data were expressed as medium (range) and compared using nonparametric (Wilcoxon and Kruskal Wallis) tests with Steel-Dawss post hoc test. Regressions were calculated by the least-squares fit (parametric) and Spearman rank correlation coefficient (nonparametric). Longitudinal data were analyzed with parametric (paired t test) and nonparametric (Wilcoxon Signed-Rank) tests. A P value ≤0.05 was considered statistically significant. Because of the comparison to urinary measurements, singlekidney imaging-derived values were averaged between the 2 kidneys of each patient. Table 1 summarizes the clinical, laboratory, and demographic data of study patients. RVH patients were older than EH patients (P=0.03). Body mass index and duration of hypertension did not differ between the groups. SBP was elevated in all hypertensive patients (P<0.05 versus HV), whereas diastolic blood pressure was similar among the groups. Mean arterial pressure was higher in hypertensive groups compared with normal (P<0.03) group. Total cholesterol and low-density lipoprotein levels and usage of antihypertensive and lipid-lowering drugs were similar in hypertensive groups. Multidetector computed tomography-derived RBF was lower in poststenotic RVH kidneys compared with EH and contralateral RVH kidneys (P<0.0001 and P=0.008, respectively). Serum creatinine levels were higher and eGFR lower in RVH patients compared with HV and EH (all P<0.0001). Urinary 24-hour protein excretion did not differ among EH and RVH groups (P=0.19).
Results

mtDNA and Renal Injury Markers
Plasma levels of COX3 and ND1 were similar among the groups (P=0.41 and P=0.85, respectively). Urinary RNAse-P copy number did not differ among the groups (P=0.97), whereas COX3 and ND1 urinary levels were elevated in hypertensive groups ( Figure 1A ). Statistical differences in urinary COX3 and ND1 copy number between the groups persisted after adjustment for age, SBP, mean blood pressure, serum creatinine, and eGFR (Table S2 in the online-only Data Supplement). Furthermore, in our validation cohort (Table  S1) , urinary COX3 and ND1 copy number remained higher in RVH patients compared with HV ( Figure S2) .
Urinary NGAL and KIM-1 levels were similarly elevated in EH and RVH ( Figure 1B ) and correlated inversely with GFR and directly with serum creatinine levels ( Figure S3) . In hypertensive patients, urinary COX3 and ND1 correlated inversely with eGFR and directly with serum creatinine, urinary NGAL, and urinary KIM-1 levels (Figure 2A-2D ). These correlations remained significant when EH and RVH each were considered alone (all P<0.05). In hypertensive patients, urinary COX3, but not ND1, correlated directly with urine protein excretion ( Figure 2E ), yet neither urinary COX3 nor ND1 urinary levels significantly correlated with SBP, diastolic blood pressure, or mean arterial pressure ( Figure S4 ). These correlations did not reach statistical significance when EH and RVH each were considered alone (all P>0.05).
mtDNA and Renal Oxygenation
BOLD-MRI ( Figure 3A ) renal cortical oxygenation was comparable between hypertensive groups, yet renal fractional hypoxia was higher in RVH compared with EH kidneys (Table 1 ). In RVH ( Figure 3B ), but not in EH patients ( Figure  S5 ), urinary COX3 and ND1 copy number correlated directly with both cortical oxygenation and fractional hypoxia, but 
Changes in mtDNA Copy Number in Treated RVH Patients
To explore the link between mtDNA and renal function, we measured urinary copy numbers of COX3 and ND1 at baseline and at 3-month follow-up in RVH patients treated with medical therapy without (n=20) or with (n=14) renal revascularization and stenting. Table 2 shows the clinical, laboratory, and demographic data of these patients. Age, body mass index, and duration of hypertension were similar between the groups, whereas fewer females were included in the revascularized group (P=0.03). SBP and diastolic blood pressure tended to be higher (P=0.08 both), and MAP was elevated in patients treated with medical therapy and revascularization (P=0.03).
The revascularized patients were taking more antihypertensive drugs but a similar number of lipid-lowering drugs compared with medically treated patients. Serum creatinine was higher and eGFR lower in revascularized patients, but urine protein excretion was similar between the groups (P=0.3). Blood pressure and medications remained unchanged 3 months after therapy in both groups, yet serum creatinine and urine protein excretion decreased, and eGFR increased (Table 2 and Figure 4A ). Urinary levels of COX3 and ND1 remained unchanged 3 months after either medical therapy alone or medical therapy plus revascularization, yet a fall in their levels was greater in revascularized compared with medically treated patients ( Figure 4B and 4C) . The change in urinary COX3 and ND1 correlated inversely with delta eGFR and directly with the change in serum creatinine ( Figure 4D and 4E).
Discussion
This study demonstrates that urinary mtDNA copy number is elevated in hypertensive patients with both EH and RVH and correlates with markers of renal injury and dysfunction. Furthermore, in RVH patients treated with medical therapy and renal revascularization, urinary mtDNA copy number varies as a function of serum creatinine and eGFR, implicating mitochondrial injury in kidney damage in human hypertension.
Emerging evidence implicates mitochondrial damage in the pathogenesis of hypertensive and ischemic renal disease. Hypertension activates several pathological mechanisms linked to mitochondrial injury, including the renin-angiotensin system, oxidative stress, inflammation, apoptosis, and renal remodeling. 3 Activation of these pathways might compromise the integrity of the inner mitochondrial membrane, allowing release of reactive oxygen species and the proapoptotic cytochrome-c to the cytosol. Reactive oxygen species selectively targets mtDNA, because it does not have effective repair mechanisms. 23 These pathways may ultimately result in impaired mitochondrial bioenergetics, swelling, cellular death, and release of mitochondrial content to the extracellular space, generating a vicious cycle of renal cellular damage.
Given the important role of mitochondria in the pathogenesis of kidney injury, we compared urinary COX3 and ND1 mtDNA copy number, surrogate markers of mitochondrial injury, between HV and hypertensive patients with EH and RVH and investigated their associations with markers of renal injury and dysfunction. COX3 encodes for the terminal enzyme of the mitochondrial respiratory chain that catalyzes the transfer of electrons from reduced cytochrome-c to oxygen, whereas ND1 encodes for one of the subunits of complex-I, an enzyme responsible for the first step in the electron transport, the transfer of electrons from NADH to ubiquinone. Urinary COX3 and ND1 copy number were found to be increased in EH and RVH compared with HV and confirmed in a validation cohort of HV and RVH subjects, suggesting mitochondrial injury and impaired energy production.
Importantly, urinary mtDNA copy number correlated with urinary levels of tubular injury markers. NGAL is a protein member of the lipocalin family heavily expressed in injured tubular cells and rapidly released into the urine, and KIM-1 is a transmembrane glycoprotein that is upregulated in tubular cells in response to ischemia. 24 We have previously demonstrated elevated urinary NGAL and KIM-1 levels in both EH and RVH patients, likely reflecting ongoing kidney inflammation and ischemia. 17 The current study extends our previous observations by demonstrating that urinary NGAL and KIM-1 levels in hypertensive patients correlate inversely with renal function, but directly with urinary COX3 and ND1, suggesting renal mitochondrial injury. Contrarily, urinary mtDNA copy number did not correlate with blood pressure, arguing against renal mitochondrial injury resulting from hypertension alone. Notably, urinary mtDNA copy number correlated directly with proteinuria and serum creatinine, and inversely with eGFR, implicating mitochondrial damage in renal dysfunction in human EH and RVH.
Mitochondrial oxidative metabolism is an important determinant of intrarenal oxygenation. In patients with mild or moderate RVH, stenotic kidney oxygenation is preserved, 13 yet this compensatory mechanism vanishes in those with severe RVH, leading to significant increases in intrarenal hypoxia. 25 BOLD-MRI offers assessment of renal cortical and medullary tissue oxygenation noninvasively in humans. Furthermore, BOLD-MRI assessment of the fractions of kidney parenchyma undergoing hypoxia correlates well with chronic underperfusion. 21 The current study demonstrates that in RVH patients both cortical and fractional hypoxia (but not RBF) correlated with urinary COX3 and ND1 copy number, suggesting a link between mitochondrial injury and impaired tissue oxygenation. Similarly, in swine RVH stenotic kidney, hypoxia is associated with mitochondrial injury and attenuated by chronic mitoprotection, 8 supporting a direct link between mitochondrial injury and renal hypoxia. Contrarily, in EH patients, urinary mtDNA copy number did not correlate with renal hypoxia, suggesting that other mechanisms (such as vascular damage) might be implicated in EH-induced mitochondrial injury. Although renal revascularization does not consistently improve GFR in human RVH, 26 in our patients, serum creatinine levels decreased and eGFR increased 3 months after medical therapy plus renal stent revascularization but remained unchanged in patients with moderate RVH treated only with medical therapy. Unlike the CORAL trial, selection of patients for renal revascularization in our study was based on clinical grounds of progressive refractory hypertension and renal insufficiency. As we and others have shown, revascularization with recent functional loss can recover 4, 5 (albeit occasionally obscured by a loss of hyperfiltration in the contralateral kidney) and reverse the degree of hypoxia. 6 Despite similar mtDNA copy number at baseline and 3 months after therapy, revascularization was associated with a greater fall in urinary COX3 and ND1 compared with medically treated patients, implying stabilization or decrease of renal mitochondrial injury. Importantly, changes in renal function during this 3-month period correlated with changes in urinary mtDNA copy number, linking renal mitochondrial injury to renal function in human hypertension.
In addition to serving as biomarkers of cellular mitochondrial damage, circulating mtDNA has been reported to induce vascular dysfunction and cardiovascular disease. 11 mtDNA possesses important inflammatogenic properties via activation of formyl peptide receptors and Toll-like receptors, propagating damage to distant organs. 27, 28 Yet, a recent study demonstrated that its systemic injection in rodents induces neither proteinuria nor renal histological abnormalities. 29 Additional studies are needed to determine if circulating mtDNA plays an active role in renal injury in human subjects.
Our observations must be interpreted cautiously. Our cross-sectional study included a relatively small number of participants, which precludes making conjectures regarding Figure 4 . Changes in urinary mitochondrial DNA copy number correlate with changes in renal function in renovascular hypertensive (RVH) patients treated with medical therapy with or without renal revascularization. A, Serum creatinine and estimated glomerular filtration rate (eGFR) in patients at baseline and 3 months after medical therapy or medical therapy+renal revascularization. B, Urinary copy number of cytochrome-c oxidase-3 (COX3) and NADH dehydrogenase subunit-1 (ND1) at baseline and 3 months after therapy in patients treated with medical therapy or medical therapy+renal revascularization. C-E, Delta (3 months-baseline) change in urinary COX3 and ND1 were lower in patients treated with medical therapy+renal revascularization compared with those treated only with medical therapy (C), inversely correlated with delta eGFR (D), but directly with delta serum creatinine levels (E). *P≤0.05 vs medical therapy. NS indicates no significant differences between baseline and 3 months after either medical therapy alone or medical therapy plus revascularization.
by guest on November 4, 2017 http://hyper.ahajournals.org/ Downloaded from the predictive value of COX3 and ND1 copy number on clinical kidney outcomes. In addition, the explanatory power of COX3 and ND1 in terms of markers of renal dysfunction in our patient population is limited (Figure 2) , which might limit their clinical use. Nevertheless, we observed similar limitations for NGAL and KIM-1 ( Figure S3 ). Furthermore, multidetector computed tomography, BOLD-MRI, and 24-hour urine protein levels were not available for HV. Three-month follow-up data of EH patients was also unavailable, precluding assessing the impact of medical therapy on mitochondrial damage. The statistical correlation with urinary NGAL and KIM-1 levels links urinary mtDNA levels to renal tubular injury. However, whether changes in urinary mtDNA copy number correlate with renal tubular mitochondrial ultrastructural alterations needs to be addressed on renal tissue samples in future studies. Unlike COX3 and ND1 copy numbers in the urine, their circulating levels were not elevated in hypertensive patients, suggesting primarily renal production. Contrarily, systemic COX3 and ND1 copy number are elevated in untreated RVH pigs. 30 Nevertheless, elevation of circulating mtDNA copy number might have been masked in our patients, who were all treated with blockers of the renin-angiotensin system and many with statins as well. Nevertheless, our results demonstrate that EH and RVH are associated with increments in urinary mitochondrial injury markers, implicating mitochondrial injury in kidney damage in human hypertension.
Perspectives
This study shows that hypertension is associated with increments in markers of mitochondrial injury, as measured by urinary mtDNA copy number. Furthermore, we found that in patients with RVH, urinary levels of mitochondrial injury markers correlate with changes in renal function after revascularization. Therefore, our observations suggest that mitochondria are implicated in renal injury and might represent a novel therapeutic target in hypertension.
Sources of Funding
This study was partly supported by the National Institutes of Health grant numbers DK73608, DK104273, HL123160, DK102325, DK100081, and DK106427 and by the Mayo Clinic Center for Regenerative Medicine. 
